Table 2.

Results of TACE as neoadjuvant therapy prior to LT in patients with HCC initially beyond MC.

Author (year)	Inclusion criteria	Transplant criteria	Outcome after LT
Graziadei et al. (2003) [206]	Beyond Milan (n = 15)	≥50 tumor regression under TACE	31% (intent-to-treat) 5-year overall survival
Millonig et al. (2007) [207]	Within UCSF Beyond UCSF	No progression beyond UCSF ≥50 tumor destruction	66.6% (response)/25% (progression) 25% 5-year overall survival
Otto et al. (2006) [208]	Beyond Milan (n = 34)	Tumor regression under TACE	74.5% 5-year overall survival
Ravaioli et al. (2008) [209]	Single HCC nodule ≤8 cm or bifocal HCC ≤5 cm or <6, each ≤4 cm, TTD ≤ 12 cm No macrovascular invasion	Downstaging into Milan criteria (TACE or resection or RFA)	75% 3-year recurrence-free survival
de Luna et al. (2009) [210]	Beyond Milan criteria	Downstaging into Milan criteria	78.8% 3-year overall survival
Jang et al. (2010) [211]	Beyond Milan criteria	Downstaging into Milan criteria	66.3% 5-year recurrence-free survival